Objectives of the Research Program. The objectives of the Research Program shall be the identification of one (1) or more Compounds or Xxxxxx Compounds suitable for further Development as Candidates and for Commercialization as Products.
Objectives of the Research Program. The objectives of the Research Program shall be the identification of Ab-MAY Products directed to one or more Holding Option Targets and Reserve Option Targets that (i) consist of one or more Lilly Antibodies conjugated to one or more MAY Compounds and (ii) are suitable for further development and commercialization as Licensed Products under an Exclusive License.
Objectives of the Research Program. The objectives of the Research Program shall be the identification of Ab-Cytotoxic Products directed to one or more Holding Option Targets and/or Reserve Option Targets that (i) consist of one or more Novartis Antibodies conjugated to one or more Cytotoxic Compounds and (ii) are suitable for further development and commercialization as Licensed Products under an Exclusive License. In the case of ImmunoGen’s conjugation of Cytotoxic Compounds to Antibodies selected by Novartis and [***], the objective of the Research Program is to identify potential Proposed Targets that are suitable for further development and commercialization of Ab-Cytotoxic Products directed to such Targets under this Agreement and an Exclusive License.
Objectives of the Research Program. The objectives of the Research Program shall be the discovery and development of Active+ Compounds for consideration by AstraZeneca so as to permit AstraZeneca to select [********]Collaboration Compounds suitable for further scientific evaluation as provided in the Research Plan. Except for the AstraZeneca Research Activities, which activities AstraZeneca shall (x) have the sole right and responsibility to conduct at its sole expense and (y) coordinate through the JRC with Targacept’s activities in the Research Program, Targacept shall have the sole right and responsibility to conduct the Research Program. Targacept shall have the right to contract with Third Parties for the conduct of any activities under the Research Plan, an Annual Research Plan or an Additional Research Plan, subject to the prior approval of AstraZeneca, not to be unreasonably withheld, conditioned or delayed; provided that Targacept shall (a) before engaging any contractor to perform such activities, [********] in good faith [********] perform such activities, (b) not unreasonably select a Third Party to conduct such activities [********], and (c) remain responsible for the performance of its obligations hereunder with respect to such activities (unless conducted by AstraZeneca). For purposes of clarity, it would not be reasonable for AstraZeneca to withhold its consent to Targacept’s contracting certain activities to a particular contractor solely because AstraZeneca wishes to perform such activities. In the event that Targacept selects AstraZeneca to conduct any activity that was originally assigned to Targacept (or a Third Party engaged by Targacept) in the Research Plan, an Annual Research Plan or an Additional Research Plan, and for which the corresponding expense was included in the applicable Targacept Research Budget, such Targacept Research Budget shall be reduced by the amount budgeted for such activity in the applicable plan. For purposes of clarity, in addition to AstraZeneca Research Activities, AstraZeneca shall have the right, in its sole discretion, to conduct research and development activities other than AstraZeneca Research Activities with respect to Collaboration Compounds, Candidate Drugs and Products during the Term, including by generating Derivatives with respect thereto. Any Derivatization of Ispronicline during the Research Program Term shall be subject to the notice to, coordination by and oversight of the JRC.
Objectives of the Research Program. The objectives of the Research Program shall be the identification of Program Aptamers for nomination by the JPT to the JSC for approval as Optimized Lead Compounds pursuant to this Agreement. Except for the TAKEDA Research Activities, if any, which shall be conducted by TAKEDA at its sole expense, ARCHEMIX shall have the primary right and responsibility to conduct the Research Program.
Objectives of the Research Program. The Research Program under this Agreement shall be defined, collectively, by the activities as described in the Research Plan for CNS and the Research Plan for Liver, each as appended to this Agreement as of the Effective Date (or as they may be amended in accordance with this Agreement). The objective of the Research Plan for CNS is for 4DMT to identify [***] ([***]) New CNS Variants that meet the applicable Delivery Success Criteria for entry into validation studies, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to provide to uniQure in order to satisfy its obligation to present [***] ([***]) New CNS Variants with the required Vector Characterization Data. The objective for the Research Plan for Liver is to identify the New Liver Variants that meet the applicable Delivery Success Criteria, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to provide to uniQure in order to satisfy its obligation to present [***] ([***]) New Liver Variants with the required Vector Characterization Data. As and to the extent provided for in the Research Plan, 4DMT would provide quantities of such New Capsid Variants to uniQure for testing. If the CNS Selection Processes or the liver Selection Processes of the Research Program do not yield at least [***] ([***]) New Capsid Variants meeting the applicable Delivery Success Criteria for entry into validation studies to generate the required Vector Characterization Data packages, then (a) if requested by 4DMT, uniQure may (but is not required to) [***]; and/or (b) [***].
Objectives of the Research Program. The objectives of the Research Program shall be the identification and preclinical development of Collaboration Compounds that exhibit activity against DS Targets.
Objectives of the Research Program. The objective of the Research Program shall be the identification of one or more Licensed Products suitable for further Development and Commercialization. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
Objectives of the Research Program. The objectives of the Research Program shall be the identification of ADCs Targeting one or more Holding Option Targets and Reserve Option Targets that (i) consist of one or more Antibodies conjugated to one or more Cytotoxic Compounds and (ii) are suitable for further development and commercialization as Licensed Products under an Exclusive License. Anything contained in this Agreement to the contrary notwithstanding, Millennium shall not furnish or use any Antibodies for making any ADCs Targeting Program Targets under the Research Program that are [***].
Objectives of the Research Program. Term; Exclusivity
